<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Singh VK</submitter><funding>Congressionally Directed Medical Research Programs</funding><funding>Armed Forces Radiobiology Research Institute/Uniformed Services University of the Health Sciences</funding><pagination>5757</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10923821</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(1)</volume><pubmed_abstract>Despite remarkable scientific progress over the past six decades within the medical arts and in radiobiology in general, limited radiation medical countermeasures (MCMs) have been approved by the United States Food and Drug Administration for the acute radiation syndrome (ARS). Additional effort is needed to develop large animal models for improving the prediction of clinical safety and effectiveness of MCMs for acute and delayed effects of radiation in humans. Nonhuman primates (NHPs) are considered the animal models that reproduce the most appropriate representation of human disease and are considered the gold standard for drug development and regulatory approval. The clinical and histopathological effects of supralethal, total- or partial-body irradiations (12 Gy) of NHPs were assessed,</pubmed_abstract><journal>Scientific reports</journal><pubmed_title>Histopathological studies of nonhuman primates exposed to supralethal doses of total- or partial-body radiation: influence of a medical countermeasure, gamma-tocotrienol.</pubmed_title><pmcid>PMC10923821</pmcid><funding_grant_id>AFR-B4-10978</funding_grant_id><funding_grant_id>W81XWH-15-C-0117</funding_grant_id><funding_grant_id>JW140032</funding_grant_id><funding_grant_id>12080</funding_grant_id><pubmed_authors>Fatanmi OO</pubmed_authors><pubmed_authors>Carpenter AD</pubmed_authors><pubmed_authors>Seed TM</pubmed_authors><pubmed_authors>Petrus SA</pubmed_authors><pubmed_authors>Lee SH</pubmed_authors><pubmed_authors>Hauer-Jensen M</pubmed_authors><pubmed_authors>Singh VK</pubmed_authors><pubmed_authors>Wise SY</pubmed_authors></additional><is_claimable>false</is_claimable><name>Histopathological studies of nonhuman primates exposed to supralethal doses of total- or partial-body radiation: influence of a medical countermeasure, gamma-tocotrienol.</name><description>Despite remarkable scientific progress over the past six decades within the medical arts and in radiobiology in general, limited radiation medical countermeasures (MCMs) have been approved by the United States Food and Drug Administration for the acute radiation syndrome (ARS). Additional effort is needed to develop large animal models for improving the prediction of clinical safety and effectiveness of MCMs for acute and delayed effects of radiation in humans. Nonhuman primates (NHPs) are considered the animal models that reproduce the most appropriate representation of human disease and are considered the gold standard for drug development and regulatory approval. The clinical and histopathological effects of supralethal, total- or partial-body irradiations (12 Gy) of NHPs were assessed,</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2026-07-14T19:37:13.236Z</modification><creation>2026-06-23T03:09:46.458Z</creation></dates><accession>S-EPMC10923821</accession><cross_references><pubmed>38459144</pubmed><doi>10.1038/s41598-024-56135-w</doi></cross_references></HashMap>